Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | NPC1 | O15118 | 8/20 | 0.69 |
| ▸ | RAB9A | P51151 | 8/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | TP53 | P04637 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.52 |
| ▸ | RELA | Q04206 | 5/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30851241 | 1.00 | KDM4E (0.69) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL25027923 | 0.84 | KDM4E (0.71) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL26745312 | 0.83 | KDM4E (0.70) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL28822907 | 0.81 | MAPT (0.64) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL27535586 | 0.81 | NPC1 (0.64) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL30129338 | 0.81 | KDM4E (0.64) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL3630700 | 0.81 | KDM4E (0.64) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL28823008 | 0.81 | MAPT (0.64) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL31344144 | 0.81 | MAPT (0.64) | KDM4ENPC1RAB9AHSD17B10TP53 | |
| SCHEMBL31239357 | 0.81 | KDM4E (0.65) | KDM4ENPC1RAB9AHSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108293281-B | Method for manufacturing photoelectric conversion element | ＡＧＣ株式会社 | 2020-04-28 | — | — | CN | disclosed |
| CN-106674145-B | The preparation method of 2- aryl benzoxazoles, 2- aryl benzothiazole compound | 复旦大学 | 2019-11-12 | — | — | CN | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| CN-106674145-A | Preparation method of 2-aryl benzoxazole and 2-aryl benzothiazole compounds | 复旦大学 | 2017-05-17 | — | — | CN | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| CN-101911832-B | Organic electroluminescent display device and method for manufacturing same | PANASONIC CORP | 2013-06-19 | — | — | CN | disclosed |
| CN-102265422-A | Organic electroluminescent device | — | 2011-11-30 | — | — | CN | disclosed |
| CN-1300521-A | Organic electroluminescent device and method for manufacturing the same | IDEMITSU KOSAN CO (JP) | 2001-06-20 | — | — | CN | disclosed |
| CN-1290119-A | Organic electroluminascent device and assembly, and method for controlling transmitted spectrum in device | KIDO JUNJI (JP) | 2001-04-04 | — | — | CN | disclosed |
| US-6171715-B1 | ANODE AND CATHODE SEPARATED IN BETWEEN BY AN ORGANIC LAYER COMPRISING AN ARYLENE BIS(SUBSTITUTED BENZOX-, BENZOTHI-, OR BENZIMIDAZOLYL) ELECTROLUMINESCENT COMPOUND; EFFICIENCY, STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| CN-1261760-A | Organic electroluminescence device | KIDO JUNJI (JP) | 2000-08-02 | — | — | CN | disclosed |
| CN-1238655-A | Organic electroluminescent devices | JUNJI KIDO (JP) | 1999-12-15 | — | — | CN | disclosed |
| CN-1236289-A | Organic electroluminescent devices | JUNJI KIDO (JP) | 1999-11-24 | — | — | CN | disclosed |
| CN-1218604-A | Multicolor organic element, method for manufacturing the same, and display using the same | CHEMIPRO K K (JP) | 1999-06-02 | — | — | CN | disclosed |
| EP-0903965-A1 | MULTICOLOR ORGANIC EL ELEMENT, METHOD FOR MANUFACTURING THE SAME, AND DISPLAY USING THE SAME | CHEMIPRO KASEI KAISHA, LIMITED (JP) | 1999-03-24 | — | — | EP | disclosed |
| CN-1190322-A | Organic Electroluminescent devices | JUNJI KIDO (JP) | 1998-08-12 | — | — | CN | disclosed |
| CN-1168132-A | organic electroluminescent device, organic thin film and triamine compound | IDEMITSU KOSAN CO (JP) | 1997-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | KDM4E 3311/4885NPC1 2477/4885RAB9A 3748/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | KDM4E 2080/4885NPC1 3637/4885RAB9A 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.